Faisal Qezvrani · Chief Marketing Officer · India
I would help directors examine the gap between an approved message and the expectation it creates outside the company. My experience includes wording I withdrew after readers understood a broader promise, a response account that needed a comparison and a central update that left older material in partner placements. Those examples provide practical questions about meaning, evidence and responsibility. They do not make me a legal adviser or give a director authority to determine individual insurance outcomes. I would ask how professional owners approve the proposition, how management learns about misunderstanding and whether the correction account reaches the public encounter. The board should understand the customer commitment and resources behind it without becoming an artwork approval panel. I would need to learn the receiving company’s own service terms and oversight arrangements before assuming that the methods used in an insurer are appropriate elsewhere.
| Capacity | Committees |
|---|---|
| Ready to join | Customer communication and conduct-risk discussions · Marketing expenditure and evidence oversight |
I would consider one non-executive contribution where experienced directors want clearer scrutiny of customer communication and the evidence behind marketing expenditure. Independent-role preparation and company-specific assessment must precede any commitment; I have no statutory experience to claim. My initial contribution could fit customer, conduct or commercial-evidence discussions under an established chair, without offering to lead a statutory committee. I would want to understand what skills already exist and why the board needs this perspective. The company should retain accountable marketing and professional management rather than expect a director to approve each campaign informally. A role built mainly around access to agencies or insurer partners would not fit. The useful contribution is to help colleagues see what the customer may understand, what the research supports and whether the organisation can correct the promise where it is actually encountered.
IICA Independent Directors’ Databank: Not yet registered
Preparation, registration where applicable and company-specific assessment remain unfinished. I have not served as a statutory director, completed a proficiency assessment or established an exemption.
Presented to the Board or a committee
Invited customer-communication and marketing-spend discussions
April 2021–present
Explains CMO recommendations, research limitations and correction work; no statutory appointment or committee vote.
Reported to a committee
Brand and comprehension accounts through the CMO
April 2015–March 2021
Prepared management evidence on reader understanding and approved messaging; executive reporting only.
Thirty-eight of sixty selected readers took a cashless-service concept as a broader payment promise. I would ask directors what evidence connects the approved wording with customer understanding, and whether a qualification can realistically repair the main impression. The subsequent review left fourteen readers unclear or mistaken, with repeated participation limiting inference about improvement. Those facts should remain visible rather than become a claim of market-wide comprehension. The board’s question is whether management can identify and correct a material expectation gap, with appropriate professional ownership. It should not decide a particular claim or rewrite the creative line during a meeting. My own approval of the earlier wording is relevant because senior confidence was part of the problem the review needed to challenge.
The additional campaign group produced thirty-three requests, while the usual-communication group produced twenty-seven from the same assigned group size. I would ask how the spending recommendation distinguishes observed response from incremental effect and how uncertainty is considered. The two-percentage-point difference was not a market forecast or proof that exactly six individuals had been caused to respond. Nor did the small comparison establish that the campaign had no value. Directors should understand the basis for further spending and the professional research work still needed. They should not choose a statistical method from the boardroom or substitute a preferred narrative for the evidence. The useful oversight habit is to ask what comparison supports the claim before a large expansion is justified by the most attractive count.
I would begin by learning how the company’s public promise is approved, distributed and corrected. Through the chair’s agreed induction, I would examine one substantial campaign decision and one example of customer misunderstanding, meeting the responsible executives through normal arrangements. I would ask how research limitations, professional approval and partner versions are reported together, and which unresolved issues reach directors. Twenty-three annual days should include preparation, meetings, induction and unexpected demands, with the actual calendar settled before acceptance. I would seek feedback on whether my questions improve collective understanding or draw the board into campaign management. A useful first-year contribution might clarify the evidence behind a customer promise and the resources needed when correction is required. It should serve a current company priority rather than impose my preferred marketing process on an organisation whose service and distribution model I am still learning.
My role exposes me to insurer campaign plans, customer research, agency terms and partner arrangements. The founder family, financial investor and employee vehicle also form part of the relationship context, even though I have no personal beneficial holding. Before confidential board material is shared, I would disclose relevant connections with insurers, agencies, research suppliers, distribution partners and investors. The receiving company should assess eligibility, independence and committee responsibilities against the actual appointment. I would not carry protected research into another company or use a board role to influence procurement at my employer. Recusal may address a particular item, but repeated absence from the customer and marketing agenda could undermine the intended contribution. Employer permission and the calendar require practical agreement. I would decline a role that depends on commercial introductions, confidential customer insight or informal endorsement of claims outside the company’s authorised professional and evidence process.
My insurer employment and agency, partner and investor relationships need appointment-specific examination. Absence of a beneficial holding does not establish independence or committee eligibility.